EUVIMEDEUVIMED entdecken
Crossref

Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway

Qi Liu, Jun Zhu, Bin Kong, Wei Shuai, He Huang

International Immunopharmacology · 2023-07 · 120 · 110311

DOI: 10.1016/j.intimp.2023.110311 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023-07. Verfasst von Qi Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, PR China; Cardiovascular Research Institute of Wuhan University, …. Hauptthemen laut MEDLINE: Sepsis, Heart Diseases. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUNDS: Sepsis-induced cardiac dysfunction is a leading cause of mortality in intensive care units. Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, possess cardio-protective, their effects on sepsis-induced cardiomyopathy remain unknown. METHODS: C57BL/6 mice received subcutaneous injections of tirzepatide once a day for 14 days before subjected to LPS challenge for 12 h. LPS-induced cardiac dysfunction and its potential mechanisms were estimated by pathological analysis, echocardiographic measurement, electrocardiography, langendorff-perfused heart and molecular analysis. RESULTS: Pretreatment with tirzepatide attenuates LPS-induced cardiac dysfunction. tirzepatide remarkably reduces LPS-mediated inflammatory responses by inhibiting the cardiac protein levels of TNF-α, IL-6, and IL-1B in mice. Interestingly, tirzepatide administration also improves cardiomyocytes apoptosis caused by LPS treatment. Furthermore, the protective roles of irzepatide against LPS-mediated increased inflammatory responses and decreased cardiomyocytes apoptosis are partially blunted by inhibiting TLR4/NF-kB/NLRP3 inflammation signaling. In addition, tirzepatide reduce the susceptibility ventricular arrhythmia in LPS-treated mice. CONCLUSION: In brief, tirzepatide attenuates LPS-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SepsisHeart DiseasesMiceAnimalsNF-kappa BLipopolysaccharidesNLR Family, Pyrin Domain-Containing 3 ProteinToll-Like Receptor 4Ventricular RemodelingMice, Inbred C57BLTirzepatide

Stichwörter der Autor:innen

Sepsis-induced cardiomyopathyTirzepatideVentricular arrhythmia

Substanzen

NF-kappa BLipopolysaccharidesNLR Family, Pyrin Domain-Containing 3 ProteinToll-Like Receptor 4Tirzepatide

Autor:innen und Institutionen

  • Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, PR China; Cardiovascular Research Institute of Wuhan University, Wuhan 430060, Hubei, PR China; Hubei Key Laboratory of Cardiology, Wuh…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, Q., Zhu, J., Kong, B., Shuai, W., & Huang, H. (2023). Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway. International Immunopharmacology, 120, 110311. https://doi.org/10.1016/j.intimp.2023.110311

Vancouver

Liu Q, Zhu J, Kong B, Shuai W, Huang H. Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway. International Immunopharmacology. 2023;120:110311. doi:10.1016/j.intimp.2023.110311

BibTeX
@article{Liu2023,
  author = {Liu, Qi and Zhu, Jun and Kong, Bin and Shuai, Wei and Huang, He},
  title = {Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway},
  journal = {International Immunopharmacology},
  year = {2023},
  volume = {120},
  pages = {110311},
  doi = {10.1016/j.intimp.2023.110311}
}
Kostenlos starten →